CN Mobile Logo

Search form


SBRT Effective in Lung Cancer Patients 80 and Older

SBRT Effective in Lung Cancer Patients 80 and Older


In this video, Richard Cassidy, MD, of the Winship Cancer Institute at Emory University in Atlanta, discusses results of a multi-center review that looked at the safety and efficacy of definitive stereotactic body radiation therapy (SBRT) in patients age 80 and older with inoperable, early-stage non–small-cell lung cancer.

The researchers identified 58 consecutive patients treated at four locations in the Atlanta area between 2010 and 2015. With a median follow-up of 19.9 months the estimated 2-year cancer-specific survival rate was 73%, with an overall survival rate of 57%. Rates of cancer-specific survival were higher for patients who were not active smokers (hazard ratio [HR], 0.14; P = .03) and were lower both for patients who had previously been diagnosed with lung cancer (HR, 7.75, P = .01) and in older patients (HR, 1.19, P = .04).

Cassidy presented the results (abstract 111) at the 2017 Multidisciplinary Thoracic Cancers Symposium, held March 16–18 in San Francisco.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.